Francois Brisebois
Stock Analyst at Oppenheimer
(1.05)
# 3,610
Out of 4,843 analysts
89
Total ratings
28.41%
Success rate
-15.75%
Average return
Main Sectors:
Stocks Rated by Francois Brisebois
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SNSE Sensei Biotherapeutics | Maintains: Outperform | $3.5 → $4 | $0.30 | +1,226.70% | 2 | Mar 28, 2025 | |
| ABEO Abeona Therapeutics | Initiates: Outperform | $16 | $6.24 | +156.62% | 1 | Mar 5, 2025 | |
| OVID Ovid Therapeutics | Upgrades: Outperform | $4 | $0.27 | +1,369.51% | 1 | Jan 29, 2025 | |
| TARS Tarsus Pharmaceuticals | Maintains: Outperform | $65 → $72 | $42.95 | +67.64% | 7 | Jan 22, 2025 | |
| MNMD Mind Medicine (MindMed) | Reiterates: Outperform | $20 | $7.26 | +175.48% | 4 | Dec 17, 2024 | |
| TRDA Entrada Therapeutics | Maintains: Outperform | $25 → $28 | $7.59 | +269.15% | 2 | Nov 6, 2024 | |
| AVDL Avadel Pharmaceuticals | Maintains: Outperform | $29 → $30 | $9.11 | +229.31% | 8 | Oct 31, 2024 | |
| PRAX Praxis Precision Medicines | Maintains: Outperform | $143 → $163 | $38.55 | +322.83% | 4 | Oct 31, 2024 | |
| HRMY Harmony Biosciences Holdings | Reiterates: Outperform | $56 → $59 | $34.50 | +71.01% | 5 | Oct 30, 2024 | |
| DYN Dyne Therapeutics | Reiterates: Outperform | $55 | $11.96 | +359.87% | 5 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $15 | $3.75 | +300.00% | 2 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $6 | $4.12 | +45.63% | 5 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $11 | $3.58 | +207.26% | 6 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $13.51 | +3.63% | 2 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $15 | $2.28 | +557.89% | 4 | Jun 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $2.22 | +1,028.67% | 1 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $55 → $65 | $31.85 | +104.11% | 5 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $10 | $2.15 | +365.12% | 2 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $5 | $0.53 | +841.09% | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $152 | $7.96 | +1,809.55% | 2 | Aug 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $63 → $36 | $21.96 | +63.93% | 4 | Aug 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $5 → $4 | $3.84 | +4.17% | 3 | Apr 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $100 → $60 | $0.29 | +20,412.82% | 3 | Apr 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7,200 → $5,400 | $3.67 | +147,038.96% | 2 | Feb 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $8.5 | $2.71 | +213.65% | 1 | Sep 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $11 | $1.56 | +605.13% | 2 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $18 | $2.11 | +755.11% | 1 | Jul 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $4.16 | +1,101.92% | 1 | Oct 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $3,240 | $1.43 | +226,473.43% | 1 | Feb 4, 2020 |
Sensei Biotherapeutics
Mar 28, 2025
Maintains: Outperform
Price Target: $3.5 → $4
Current: $0.30
Upside: +1,226.70%
Abeona Therapeutics
Mar 5, 2025
Initiates: Outperform
Price Target: $16
Current: $6.24
Upside: +156.62%
Ovid Therapeutics
Jan 29, 2025
Upgrades: Outperform
Price Target: $4
Current: $0.27
Upside: +1,369.51%
Tarsus Pharmaceuticals
Jan 22, 2025
Maintains: Outperform
Price Target: $65 → $72
Current: $42.95
Upside: +67.64%
Mind Medicine (MindMed)
Dec 17, 2024
Reiterates: Outperform
Price Target: $20
Current: $7.26
Upside: +175.48%
Entrada Therapeutics
Nov 6, 2024
Maintains: Outperform
Price Target: $25 → $28
Current: $7.59
Upside: +269.15%
Avadel Pharmaceuticals
Oct 31, 2024
Maintains: Outperform
Price Target: $29 → $30
Current: $9.11
Upside: +229.31%
Praxis Precision Medicines
Oct 31, 2024
Maintains: Outperform
Price Target: $143 → $163
Current: $38.55
Upside: +322.83%
Harmony Biosciences Holdings
Oct 30, 2024
Reiterates: Outperform
Price Target: $56 → $59
Current: $34.50
Upside: +71.01%
Dyne Therapeutics
Sep 3, 2024
Reiterates: Outperform
Price Target: $55
Current: $11.96
Upside: +359.87%
Aug 19, 2024
Reiterates: Outperform
Price Target: $15
Current: $3.75
Upside: +300.00%
Aug 16, 2024
Reiterates: Outperform
Price Target: $6
Current: $4.12
Upside: +45.63%
Aug 15, 2024
Reiterates: Outperform
Price Target: $11
Current: $3.58
Upside: +207.26%
Aug 14, 2024
Reiterates: Outperform
Price Target: $14
Current: $13.51
Upside: +3.63%
Jun 26, 2024
Maintains: Outperform
Price Target: $11 → $15
Current: $2.28
Upside: +557.89%
Jun 25, 2024
Initiates: Outperform
Price Target: $25
Current: $2.22
Upside: +1,028.67%
Jun 13, 2024
Maintains: Outperform
Price Target: $55 → $65
Current: $31.85
Upside: +104.11%
May 6, 2024
Reiterates: Outperform
Price Target: $10
Current: $2.15
Upside: +365.12%
Apr 1, 2024
Reiterates: Outperform
Price Target: $5
Current: $0.53
Upside: +841.09%
Aug 30, 2023
Reiterates: Outperform
Price Target: $152
Current: $7.96
Upside: +1,809.55%
Aug 17, 2023
Maintains: Outperform
Price Target: $63 → $36
Current: $21.96
Upside: +63.93%
Apr 4, 2023
Maintains: Outperform
Price Target: $5 → $4
Current: $3.84
Upside: +4.17%
Apr 3, 2023
Maintains: Outperform
Price Target: $100 → $60
Current: $0.29
Upside: +20,412.82%
Feb 6, 2023
Maintains: Outperform
Price Target: $7,200 → $5,400
Current: $3.67
Upside: +147,038.96%
Sep 7, 2022
Initiates: Outperform
Price Target: $8.5
Current: $2.71
Upside: +213.65%
Aug 29, 2022
Maintains: Outperform
Price Target: $17 → $11
Current: $1.56
Upside: +605.13%
Jul 18, 2022
Assumes: Outperform
Price Target: $18
Current: $2.11
Upside: +755.11%
Oct 29, 2021
Initiates: Outperform
Price Target: $50
Current: $4.16
Upside: +1,101.92%
Feb 4, 2020
Initiates: Buy
Price Target: $3,240
Current: $1.43
Upside: +226,473.43%